UNSPSC 51312701: Clemastine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95QN29S1ID. European Medicines Agency schedules Clemastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06648MIG. Clemastine generally arises in the molecular formula C21H26CLNO.

UNSPSC 51312701 Clemastine is a Commodity code tracking pharmaceutical products purchased by state and local health agencies, though recent opportunities posted under this code reflect a broader set of acquisitions than the code's specific drug designation. State and local governments use this code to procure pharmaceuticals, over-the-counter medications, and related medical supply systems to support public health operations, emergency response, and community health initiatives. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across multiple participating jurisdictions and agencies. Purchases range from individual pharmaceutical products with specific National Drug Codes (NDCs) to bundled acquisitions of naloxone, drug deactivation systems, and generic multi-source medications distributed through authorized wholesalers to state and local facilities.

Recent activity appears concentrated in Florida and Minnesota, with exploratory procurement underway in Texas. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, response due July 26, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating jurisdictions including Oregon, with proposals due March 26, 2026; vendors must work through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson and comply with cGMP, DSCSA certification, and price competitiveness weighted at 75 percent of evaluation. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription fulfillment capabilities to inform future state procurement strategy, though this remains preliminary information-gathering rather than a formal competitive solicitation.